Growth Momentum Revenue dynamics show mix shifts with total quarterly revenue around $20.1M and product revenue at $14.5M, signaling strong product demand but a softer services mix; opportunity to upsell premium multi-omic solutions and managed service offerings to drive higher margin growth.

Strategic Divestitures Plans to sell the Mass Cytometry business to Multiplex and a potential merger with Treeline Biosciences indicate ongoing strategic realignment; position as a partner for integration, post-transaction continuity services, and cross-sell of core proteomics and spatial biology capabilities.

Distribution Expansion Distribution partnership with DKSH to reach Australia and New Zealand highlights appetite for channel-led growth; leverage this network to promote spatial biology, proteomics and genomics solutions into regional labs and research centers.

Investment Readiness Significant funding and sizable revenue scale imply readiness for larger multi-year procurement deals and enterprise collaborations; target large research institutions and contract research organizations with bundled omics platforms, data analytics, and cloud-enabled workflows.

Industry Collaboration Track record of events and roundtables plus AACR participation demonstrates thought leadership and ecosystem engagement; leverage these platforms to co-sell with collaborators, secure pilot programs, and accelerate adoption of new proteomics and single-cell technologies.